IS

The benefits of individualised aminoglycoside dosing

Severely ill patients may benefit from pharmacokinetically-determined individualised aminoglycoside dosing.

PHARMACOLOG Y

In a study involving 47 patients receiving aminoglycoside therapy, mortality was significantly reduced in severely ill patients who received individualised therapy, compared with patients who received conventional therapy (1/8 vs 5/8, respectively); however, there was no significant difference in mortality for patients with less severe disease.

The decrease in mortality may have been in part the result of the significantly greater dosages of aminoglycosides received by individualised therapy recipients. Notably, there was no difference between groups for toxicity. Whipple JK. Ausman RK. Franson T. Quebbeman EJ. Effect of IOdiyidualizcd pharmacokinc\lc dosing on patient outcome. Critical Care Medicine 19: 1480-1485, Dec 1991 ""

14 Mar 1992INPHARMA® ISSN0156-2703!92!0314-0018!$1.00!O © Adislnlemationol lid